Taligen Therapeutics is a technology company.
Taligen Therapeutics has raised $79.0M across 3 funding rounds.
Taligen Therapeutics has raised $79.0M in total across 3 funding rounds.
Taligen Therapeutics has raised $79.0M in total across 3 funding rounds.
Taligen Therapeutics's investors include Buff Gold Ventures, Versant Ventures.
Taligen Therapeutics was a development-stage biotechnology company focused on discovering and developing novel protein therapeutics that regulate the complement system to treat inflammatory and immune diseases.[3][4][6] It targeted unmet needs in areas like asthma, traumatic brain injury, autoimmune diseases, and ophthalmic conditions such as age-related macular degeneration (AMD), serving patients with severe inflammatory disorders through preclinical monoclonal antibodies and recombinant fusion proteins.[1][2][3][6] The company built promising candidates inhibiting complement inflammatory pathways but was acquired by Alexion Pharmaceuticals in January 2011 for an upfront $111 million plus contingent milestone payments, ending its independent operations and integrating its pipeline into Alexion's broader portfolio for hematologic, kidney, neurologic, and other diseases.[1][2][7]
Taligen Therapeutics was founded in March 2004 by V. Michael Holers, M.D., a University of Colorado School of Medicine professor, and Woodruff Emlen, M.D., who served as CEO and co-founder.[3][6] The idea emerged from academic research at the University of Colorado, licensing technology to manipulate complement proteins—key amplifiers in the immune system's inflammation process—for therapeutic use.[3][6] Early traction included CU's proof-of-concept investment in 2005, the 2008 University of Colorado Technology Transfer Office bioscience company of the year award, and Series B funding led by Clarus Ventures, Alta Partners, Sanderling Ventures, and High Country Venture.[6] By 2011, under CEO Abbie Celniker, Ph.D., Taligen's preclinical progress led to its acquisition by Alexion, with Celniker heading Alexion's new Translational Medicine Group.[1][2][6]
Taligen rode the early 2000s wave of complement biology research, a trend gaining traction for treating rare and inflammatory diseases where traditional immunosuppressants fell short.[1][3][4] Timing was ideal amid growing recognition of complement's role in amplification loops for conditions like PNH (treated by Alexion's Soliris), positioning Taligen's inhibitors as complementary assets.[1][2][6] Market forces favoring biotech acquisitions of academic spinouts propelled its $111 million buyout, influencing the ecosystem by validating university tech transfer—earning CU awards—and bolstering Alexion's portfolio for global expansion in severe disease therapies.[2][6][7]
Post-2011 acquisition, Taligen's independent story ended, but its technologies fueled Alexion's (later AstraZeneca's) complement-focused pipeline, potentially advancing treatments for AMD and inflammation.[1][2] Future influence lies in integrated compounds reaching milestones for contingent payments, shaped by ongoing complement inhibitor trends amid rising autoimmune and ophthalmic demands. This underscores how nimble biotechs like Taligen amplify big pharma's innovation, turning academic insights into patient therapies.[1][7]
Taligen Therapeutics has raised $79.0M across 3 funding rounds. Most recently, it raised $10.0M Series B in August 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2010 | $10.0M Series B | Buff Gold Ventures | |
| Dec 1, 2007 | $65.0M Series B | Buff Gold Ventures, Versant Ventures | |
| Jul 1, 2005 | $4.0M Series A | Buff Gold Ventures |